SG
IBB icon

Societe Generale’s iShares Biotechnology ETF IBB Stock Holding History

Societe Generale’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$63.1M Buy
+735,930
New +$66M 0.45% 26

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Societe Generale's IBB Position: Q2 2016 in Review

Societe Generale opened a new position in iShares Biotechnology ETF (IBB) in Q2 2016: 735,930 shares worth $63.1M. The stake represents 0.45% of the portfolio and ranks #26 among its holdings.

428 funds tracked by Wall St. Rank hold IBB as of Q2 2016.

  • Societe Generale held 735,930 shares of iShares Biotechnology ETF worth $63.1M as of Q2 2016.
  • iShares Biotechnology ETF was a new Societe Generale position in Q2 2016.
  • iShares Biotechnology ETF made up 0.45% of Societe Generale's portfolio in Q2 2016, its #26 holding.
  • 428 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.